Latest Artemisinin Stories
Chinese malaria drugs giant, Guilin, launches effort in Africa to enable patients and consumers detect fake malaria drugs using mobile phone technology, goldkeys. Shanghai,
On April 11, the pharmaceutical company Sanofi will launch the large-scale production of a partially synthetic version of artemisinin, a chemical critical to making today's front-line antimalaria drug, based on Keasling's discovery.
Early diagnosis and treatment with antimalarial drugs (ACTs—artemisinin based combination treatments) has been linked to a reduction in malaria in the migrant population living on the Thai-Myanmar border, despite evidence of increasing resistance to ACTs in this location.
New research has revealed that immature malaria parasites are more resistant to treatment with key antimalarial drugs than older parasites, a finding that could lead to more effective treatments for a disease that kills one person every minute and is developing resistance to drugs at an alarming rate.
Malaria brings misery and death to millions in the developing world each year, and fighting it keeps medical researchers up at night because the mosquito-borne parasite Plasmodium falciparum, which causes the deadliest form of the disease, has developed resistance to every drug thrown at it.
University of Maryland School of Medicine researchers have launched groundbreaking research into the spread of potentially deadly drug-resistant malaria in the developing Southeast Asian nation of Myanmar, also known as Burma.
Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed.